

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

13 May 2025



**Eden Research plc**  
("Eden" or "the Company")

#### **Approval of Mevalone® to control powdery mildew in Californian grapes**

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technology, is pleased to announce the approval of its flagship product, the fungicide Mevalone®, for the control of powdery mildew in grapes in California. This latest regulatory approval extends the use of Mevalone on grapes in California, where it is already approved for the control of Botrytis cinerea.

Sipcam Agro USA, which already acts as the Company's exclusive distributor for Mevalone in the US, will now actively promote Mevalone for this new use, providing even more versatility for growers. It is expected that the label and marketing materials detailing the use of Mevalone for the control of powdery mildew will be updated for the current growing season. While the Company believes that the inclusion of powdery mildew to the label adds to the applicability of Mevalone for farmers and increases the chance of achieving a greater market share among botryticides, it does not expect to change its revenue expectations in the near term.

Powdery mildew is a fungal disease that affects many crops. Eden estimates that the total addressable market for Mevalone in the US is in the region of €94 million, with California representing the largest share of this potential by a substantial margin.

California leads US grape production, and powdery mildew and Botrytis severely impact California grape production, with the former representing the most prevalent fungal disease affecting grapes. Eden's solution not only provides a residue-free, plant-based option to vineyard managers but also represents an effective tool when compared to its conventional alternatives.

#### **Sean Smith, Chief Executive Officer of Eden Research, commented:**

"This approval in the leading US grape production state shows Eden's commitment to supporting sustainable agriculture across regions with the highest standards of efficacy, quality and safety. California's grape growers can now use Mevalone with protocols and application methods similar to those in Italy or Spain, where powdery mildew significantly impacts grape production and quality. With this regulatory approval, Eden expands the potential for Mevalone in the US."

#### **Brent Marek, CEO of Sipcam Agro USA, commented:**

"Speaking to grape growers across California, Botrytis and powdery mildew are without question two of the most critical diseases affecting production in California. With today's approval, growers are now afforded a better and more effective tool to manage powdery mildew with a novel mode of action that is well recognised by experts in agronomy and fungicide resistance in many other countries. We're also pleased this approval has arrived in time for the start of the 2025 season. Sipcam Agro USA has a strong commitment to the success of the product, as reflected in the considerable marketing resources we've allocated to this product."

-- ENDS --

For further information contact:

**Eden Research plc**

Sean Smith  
Alex Abrey

[www.edenresearch.com](http://www.edenresearch.com)  
01285 359 555

**Cavendish Capital Markets Limited**  
(Nominated advisor and joint broker)

Giles Balleny / George Lawson (corporate finance)  
Charlie Combe (corporate broking)  
Michael Johnson (sales)

020 7220 0500

**Oberon Capital (Joint broker)**

Nick Lovering  
Mike Seabrook  
Adam Pollock

020 3179 5300

**Hawthorn Advisors (Financial PR)**

Victoria Ainsworth

[eden@hawthornadvisors.com](mailto:eden@hawthornadvisors.com)

**Notes to Editors:**

**Eden Research** is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

Based on plant-derived active ingredients, **Mevalone**<sup>®</sup> is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

**Novellus**<sup>®</sup> is an evolution of Mevalone, allowing improved rates in the field, high levels of efficacy and a broader list of targets.

**Cedroz**<sup>™</sup> is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

Eden's seed treatment product, **Ecovelex**<sup>™</sup> was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, US and elsewhere, and formulated using Eden's Sustaine<sup>®</sup> microencapsulation system.

Eden's **Sustaine**<sup>®</sup> encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease of use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange **Green Economy Mark** in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

For more information about Eden, please visit: [www.edenresearch.com](http://www.edenresearch.com). You can also follow Eden's latest developments via its social media channels: [X \(Twitter\)](#) and [LinkedIn](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

REAKLLFFEELBBBQ